Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer’s disease with hydromethylthionine mesylate using external control data

B. Schelter; Helen Shiells; Serena Lo; Nafeesa Nazlee; Emily Evans; Peter Bentham; Serge Gauthier; Henrik Zetterberg; Gordon K Wilcock; Lutz Froelich; Alistair Burns; Emer MacSweeney; Clive Ballard; Jin-Tai Yu; Tay Siew Choon; Vahe Asvatourian; Natalia Muehlemann; Jan Priel; Karin Kook; Tenecia Sullivan; Diane Downie; Sonya Miller; Carol Pringle; John M․D Storey; Tom Baddeley; Charles R Harrington; Roger Staff; Anca-Larisa Sandu; Claire Hull; Richard Stefanacci; Claude M Wischik

doi:10.1016/j.tjpad.2026.100560

Key Points

Evaluate the efficacy of hydromethylthionine mesylate in treating tau pathology associated with mild cognitive impairment and Alzheimer's disease.
Compared HMTM treatment with existing control data from CPAD and ADNI.
Utilized meta-analytic controls for broader analysis of treatment efficacy.
Evidence suggests HMTM treatment offers significant clinical benefits.
Treatment was found to be accessible with low burden for both patients and physicians.

Implication

Clinical assessment demonstrates potential benefit of HMTM in treating tau pathology in Alzheimer's Disease, suggesting wider access to therapies.

Abstract

Comparisons of HMTM treatment with CPAD, ADNI, and meta-analytic controls provide evidence consistent with clinical benefit HMTM. It has the potential to offer an accessible oral treatment option which could be delivered with minimal patient/physician burden.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schelter et al. (2026) studied this question.

synapsesocial.com/papers/69e7132bcb99343efc98cf4b https://doi.org/10.1016/j.tjpad.2026.100560

View Full Paper

Ask AI

Bookmark

Share

Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer’s disease with hydromethylthionine mesylate using external control data

Key Points

Implication

Abstract

Discussion

Cite This Study

Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer’s disease with hydromethylthionine mesylate using external control data

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading